Swiss pharmaceutical giant Novartis is reportedly exploring a potential acquisition of Avidity Biosciences, a clinical-stage biotech focused on RNA-based medicines, according to The Financial Times. This rumored buyout highlights Novartis’s ongoing strategy to expand its drug development portfolio by targeting innovative genetic medicine platforms—particularly those leveraging RNA as a therapeutic modality.

Though discussions remain preliminary and there is no certainty a deal will materialize, industry analysts are paying close attention, as such a move would reflect broader trends in the global pharmaceutical landscape. The chase for advanced platform technologies—especially those in RNA and gene editing—has intensified throughout 2024 and into 2025, largely fueled by the success of mRNA vaccines and therapies, as well as the growing prevalence of rare diseases and difficult-to-treat conditions.

Why Novartis Might Target Avidity Biosciences

Avidity Biosciences has become a leading player in the field of RNA therapeutics. The company’s proprietary Antibody Oligonucleotide Conjugates (AOC™) platform allows for targeted delivery of oligonucleotide therapies to specific tissues, potentially achieving higher efficacy and improved safety compared to earlier generations of RNA drugs.

Avidity’s pipeline addresses a range of rare muscle diseases, including:

• Facioscapulohumeral muscular dystrophy (FSHD)
• Myotonic dystrophy type 1 (DM1)
• Duchenne muscular dystrophy (DMD)

Its lead candidate, delpacibart etedesiran (AOC 1001) for DM1, has shown promising early-stage clinical data, spurring greater interest from larger pharma companies seeking to diversify their pipelines with first-in-class or best-in-class therapies for underserved conditions.

Novartis, with a stated goal of focusing its portfolio on high-value innovative medicines, has prioritized investments in targeted therapies and advanced platforms. In recent years, the company concluded several significant acquisitions and divestitures, including the $16 billion sale of its generics unit Sandoz, a move that allowed it to sharpen its focus and pursue high-potential assets in oncology, immunology, and gene therapies.

Biopharma M&A: An Intensifying Race

After a slow 2022, merger and acquisition activity in the biotech and pharma sector roared back in 2023 and 2024. Large pharmaceutical groups, facing the looming impact of major patent cliffs and pricing pressures, scrambled to replenish their flagging pipelines. According to PwC’s 2024 pharma deals outlook, total M&A deal values exceeded $190 billion globally in 2024—up more than 40% from the prior year.

RNA platform companies are particularly coveted, given their demonstrated capability in the COVID-19 era and emerging use for conditions such as cancers, muscular dystrophies, and rare genetic disorders. The market for RNA therapeutics—a segment that includes siRNA, antisense oligonucleotides, and mRNA medicines—is projected to reach over $25 billion by 2030 (Global RNA Therapeutics Market Report).

Novartis, by showing interest in Avidity, signals a competitive intent to secure a seat at the RNA innovation table amidst rivals like Pfizer, Roche, and Sanofi, all of which have increased partnership and M&A activity around genetic medicines.

What a Novartis–Avidity Deal Could Look Like

While terms of a potential offer were not disclosed and neither company has officially commented, analysts estimate that a buyout could value Avidity Biosciences at a significant premium over its recent trading price. As of Q2 2025, the company maintained a market capitalization of over $2.2 billion, buoyed by positive readouts from its lead RNA programs and growing investor confidence in the AOC platform.

Recent precedent transactions in rare diseases and RNA therapeutics suggest a possible acquisition could land in the $3–4 billion range, depending on pipeline milestones and competitive interest. Avidity’s relatively de-risked clinical pipeline, experienced management, and robust patent estate add to its attractiveness as an M&A target.

If consummated, the deal would allow Novartis to:

• Expand its capabilities in precision neuromuscular and rare disease therapies
• Gain first-mover access to Avidity’s proprietary AOC technology
• Realize potential operational synergies and extend existing RNA research programs

For Avidity, the backing of a global pharmaceutical leader would open doors to accelerated global clinical development, larger-scale commercialization, and resources needed to bring its therapies to a broader patient base.

The Competitive and Regulatory Environment

Given growing scrutiny of biopharma consolidation in the US and Europe, any such acquisition would likely be assessed closely by regulators for its potential impact on innovation and competition. Recent US Federal Trade Commission actions have targeted deals perceived to diminish patient choice or limit R&D independence, leading to greater due diligence and occasionally delayed or blocked transactions.

Nonetheless, industry experts anticipate that deals which help accelerate the development of therapies for high-unmet-need medical conditions—such as neuromuscular diseases—would stand a better chance of speedy approval, provided that market competition is maintained.

Outlook: High-Stakes Moves in the Biotech Market

As the pharmaceutical sector updates its playbook to include more RNA- and gene-based medicines, competitive tension is expected to drive further consolidation and deal-making activity into 2025 and beyond. For Novartis, a possible acquisition of Avidity Biosciences would not only extend its reach into a cutting-edge technology area, but also answer mounting pressure to deliver pipeline growth and innovation.

While the deal is far from certain—with the possibility of rival offers or strategic partnerships also in play—one thing is clear: The global race for the next generation of biotech assets is heating up, and platform technologies like Avidity’s could define the future of precision medicine. Investors, patients, and biotech professionals will be watching closely as developments unfold.